Clinical trial
Safety of GM-CT-01 With and Without 5-Fluorouracil in Patients With Solid Tumors
NCT00054977 · Galectin Therapeutics Inc., Industry · Completed
Key facts
| NCT number | NCT00054977 |
|---|---|
| Title | Safety of GM-CT-01 With and Without 5-Fluorouracil in Patients With Solid Tumors |
| Official title | A Phase I Open-Label Study to Evaluate the Safety and Tolerability of Escalating Doses of GM-CT-01 in the Presence and Absence of 5-Fluorouracil (5-FU) in Subjects With Advanced Solid Tumors |
| Lead sponsor | Galectin Therapeutics Inc., Industry |
| Status | Completed |
| Phase | Phase 1 |
| Study type | Interventional |
| Conditions | Colorectal Cancer, Lung Cancer, Breast Cancer, Head and Neck Cancer, Prostate Cancer |
| Intervention type | Drug |
| Interventions | GM-CT-01, 5-fluorouracil |
| Enrollment | 40 |
| Start date | Feb 1, 2003 |
| Primary completion | Apr 1, 2005 |
| Completion | Sep 1, 2006 |
| First posted | Feb 17, 2003 |
| Last update posted | Mar 12, 2012 |
| Countries | United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: